Cargando…
Unraveling the clinicopathological features driving the emergence of ESR1 mutations in metastatic breast cancer
ESR1 mutations were recently found to be an important mechanism of endocrine resistance in ER-positive (ER + ) metastatic breast cancer. To determine the clinicopathological features driving the emergence of the ESR1 mutations we studied plasma cfDNA and detailed clinical data collected from patient...
Autores principales: | Kuang, Yanan, Siddiqui, Bilal, Hu, Jiani, Pun, Matthew, Cornwell, MacIntosh, Buchwalter, Gilles, Hughes, Melissa E., Wagle, Nikhil, Kirschmeier, Paul, Jänne, Pasi A., Paweletz, Cloud P., Lin, Nancy U., Krop, Ian E., Barry, William T., Winer, Eric P., Brown, Myles, Jeselsohn, Rinath |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6072793/ https://www.ncbi.nlm.nih.gov/pubmed/30083595 http://dx.doi.org/10.1038/s41523-018-0075-5 |
Ejemplares similares
-
ESR1 fusions and therapeutic resistance in metastatic breast cancer
por: Nagy, Zsuzsanna, et al.
Publicado: (2023) -
Corrigendum: ESR1 fusions and therapeutic resistance in metastatic breast cancer
por: Nagy, Zsuzsanna, et al.
Publicado: (2023) -
How drug resistance takes shape
por: Jeselsohn, Rinath, et al.
Publicado: (2016) -
VIPER: Visualization Pipeline for RNA-seq, a Snakemake workflow for efficient and complete RNA-seq analysis
por: Cornwell, MacIntosh, et al.
Publicado: (2018) -
Phase II study of tivantinib (ARQ 197) in patients with metastatic triple-negative breast cancer
por: Tolaney, Sara M., et al.
Publicado: (2015)